Blockchain Registration Transaction Record

Nexalin Technology Unveils Positive Results of Clinical Study for Gen-2 tACS Device

Nexalin Technology CEO Mark White shares positive results from a clinical study evaluating the Gen-2 tACS device for reducing pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study was conducted at The University of California, San Diego, showing promising outcomes and hope for effective treatment options.

The positive results from this study offer hope for individuals suffering from mTBI, potentially improving their quality of life and providing effective treatment options in the future. The innovative approach by Nexalin Technology could significantly impact the traumatic brain injuries assessment market, which is projected to reach over $7.2 billion by 2032.